<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01895088</url>
  </required_header>
  <id_info>
    <org_study_id>ACU-P12-020C</org_study_id>
    <nct_id>NCT01895088</nct_id>
  </id_info>
  <brief_title>A Continuation Study To Monitor The Long Term Safety Of Patients Completing Protocols ACU-P08-020/020A</brief_title>
  <official_title>A Continuation Study To Monitor The Long Term Safety Of The AcuFocus â„¢ ACI 7000PDT Patients Completing Protocols ACU-P08-020/020A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AcuFocus, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AcuFocus, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2 year follow up study to monitor the long term safety of the ACI 7000PDT in
      subjects who are still implanted with the ACI and have successfully completed the
      ACU-P08-020/020A studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two year follow up study designed to monitor and obtain long-term safety data of
      the ACI 7000PDT in subjects who participated and successfully completed the ACU-P08-020/020A
      studies. Subjects must be able to provide voluntary informed consent, and must sign and be
      given a copy of the written Informed Consent form prior to participating. This continuation
      study follows subjects still implanted with the ACI and includes two visits, at 12-month
      intervals, after subjects have been exited (at Month 36) from the ACU-P08-020/020A studies.
      The first visit is at Month 48 following implantation followed by a final Month 60 visit. The
      study parameters being measured at these two visits include:

        -  Specular microscopy

        -  Slit lamp and fundus examination (ocular health)

        -  Corrected and uncorrected visual acuity

        -  Manifest mid-point refraction

        -  Corneal topography

        -  Dry eye assessment

        -  Mesopic and Photopic contrast sensitivity

        -  Adverse events and complications

      All sites participating in the ACU-P08-020/020A studies were invited to participate in the
      continuation study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change (Increase) in Uncorrected Near Visual Acuity</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>The change in the number of lines of threshold visual acuity achieved postoperatively.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Patients prev. impl. with ACI 7000 PDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AcuFocus Corneal Inlay ACI 7000 PDT</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcuFocus Corneal Inlay ACI 7000 PDT</intervention_name>
    <description>Inlay implanted in cornea for improvement of near vision</description>
    <arm_group_label>Patients prev. impl. with ACI 7000 PDT</arm_group_label>
    <other_name>AcuFocus KAMRA inlay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have completed participation in the ACU-P08-020/020A clinical trial.

          -  Patients must be able to provide voluntary informed consent, and must sign and be
             given a copy of the written Informed Consent form.

        Exclusion Criteria:

          -  Patients who did not complete ACU-P08-020/020A.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Durrie, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Durrie Vision</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chad Betts, M.D., R.Ph</last_name>
    <role>Principal Investigator</role>
    <affiliation>MacDonald Eye Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vance Thompson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vance Thompson Vision</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jay Pepose, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pepose Vision Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Waltz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Surgeons of Indiana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Vukich, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davis Duehr Dean</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Hersh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornea and Laser Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Tooma, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NVision</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Colman Kraff, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kraff Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Maloney, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maloney Vision Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott MacRae, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester Eye Institute - Strong Vision</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Foster, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye Center of Northern Colorado</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phillip Hoopes, Sr., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hoopes Vision</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McDonald Eye Associates</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maloney Vision</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NVision</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Center NOCO</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kraff Eye Institute</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Surgeons of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durrie Vision</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pepose Vision Institute</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cornea &amp; Laser Eye Institute, P.A</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Eye Institute - Strong Vision</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoopes Vision</name>
      <address>
        <city>Sandy City</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davis Duehr Dean</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.acufocus.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2013</study_first_submitted>
  <study_first_submitted_qc>July 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <results_first_submitted>April 3, 2017</results_first_submitted>
  <results_first_submitted_qc>May 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2017</results_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>presbyopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients Prev. Implanted With ACI7000PDT</title>
          <description>Prev. implanted in ACU-P08-020/020A study
AcuFocus Corneal Inlay ACI 7000 PDT: corneal inlay</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="271">1 subject consented for monitoring after device removal (not included in cohort), per FDA request.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="253"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Age, Categorical</title>
          <description>Measure Type: Count of Participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="271"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="271"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change (Increase) in Uncorrected Near Visual Acuity</title>
        <description>The change in the number of lines of threshold visual acuity achieved postoperatively.</description>
        <time_frame>Baseline and 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Prev. Implanted With ACI7000PDT</title>
            <description>Prev. implanted in ACU-P08-020/020A study
AcuFocus Corneal Inlay ACI 7000 PDT: Inlay implanted in cornea for improvement of near vision</description>
          </group>
        </group_list>
        <measure>
          <title>Change (Increase) in Uncorrected Near Visual Acuity</title>
          <description>The change in the number of lines of threshold visual acuity achieved postoperatively.</description>
          <units>lines of visual acuity improvement</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Two years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients Prev. Implanted With ACI7000PDT</title>
          <description>Prev. implanted in ACU-P08-020/020A study
AcuFocus Corneal Inlay ACI 7000 PDT: corneal inlay</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Carcinoma</sub_title>
                <description>Mucoepidermoid carcinoma of left mandibular gland</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Motorcycle Accident</sub_title>
                <description>Broken collar bone and six broken ribs</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <description>Pontine Hemorrage, Hypertensive Emergency</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Joint Replacement Surgery</sub_title>
                <description>Two knee, one hip</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Benign Brain Tumor</sub_title>
                <description>Parathyroid gland</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Cyst Removal</sub_title>
                <description>Synovial cyst</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <description>Meibomian gland dysfunction</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Secondary Surgical Intervention</sub_title>
                <description>Treatment of hyperopic shift - inlay in place (3) Inlay removal</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Superficial Punctate Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Conjunctival cyst</sub_title>
                <description>OS</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Retinal pigment epithelium granularity</sub_title>
                <description>Retinal changes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <description>OS poked by tree branch - resolved in four days</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="271"/>
              </event>
              <event>
                <sub_title>Vision</sub_title>
                <description>Decrease in BCDVA two lines at Month 3 or later</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="271"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eugenia Thomas, Director Clinical Trials</name_or_title>
      <organization>AcuFocus, Inc.</organization>
      <phone>9495859511</phone>
      <email>nthomas@acufocus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

